BridgeBio Pharma, Inc. (BBIO) P/E Ratio History
Historical price-to-earnings valuation from 2026 to 2026
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of February 28, 2026, BridgeBio Pharma, Inc. (BBIO) trades at a price-to-earnings ratio of -17.5x, with a stock price of $66.48 and trailing twelve-month earnings per share of $-3.70.
Compared to the Healthcare sector median P/E of 23.7x, BBIO trades at a 174% discount to its sector peers. The sector includes 224 companies with P/E ratios ranging from 0.0x to 184.4x.
Relative to the broader market, BBIO trades at a notable discount to the S&P 500 median P/E of 26.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our BBIO DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
Peer Comparison
P/E metrics vs. Commercial Rare Disease Biopharma peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
VRTXVertex Pharmaceuticals Incorporated | $126B | 32.4 | 3.91 | +837% |
BMRNBioMarin Pharmaceutical Inc. | $12B | 34.3 | - | +1186%Best |
PTCTPTC Therapeutics, Inc. | $5B | 8.8 | - | +264% |
CORTCorcept Therapeutics Incorporated | $4B | 43.5 | - | -33% |
CPRXCatalyst Pharmaceuticals, Inc. | $3B | 13.7 | 0.73Best | +28% |
BCRXBioCryst Pharmaceuticals, Inc. | $2B | 7.2Lowest | - | +381% |
HRMYHarmony Biosciences Holdings, Inc. | $2B | 10.5 | - | +8% |
PLXProtalix BioTherapeutics, Inc. | $218M | 78.7 | - | -63% |
SLNOSoleno Therapeutics, Inc. | $145,692 | 100.2 | - | +109% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
See BBIO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BBIO Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare BBIO vs AGIO
See how BBIO stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is BBIO stock overvalued or undervalued?
BBIO current P/E: -17.5x. 5-year average P/E: N/A. Percentile: N/A.
How does BBIO's valuation compare to peers?
BridgeBio Pharma, Inc. P/E of -17.5x compares to sector median of 23.7x. The discount suggests lower growth expectations or higher risk.
What is BBIO's PEG ratio?
BBIO PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2026-2026.